Local biotech’s cancer drug produced bad test results
Tuesday, February 14, 2006
It sounds like deja vu. Last year a drug to be produced at the $400 million manufacturing plant in Oceanside was pulled by the FDA after several subjects in final testing died. But news of seven deaths in trials of Genentech's cancer drug Avastin does not affect plans to manufacture the drug at the Oceanside plant, according to Christina Becker of Genentech. She says will Avastin is still approved for advanced colorectal cancer patients.
AVASTIN: "And we'll be filing with the FDA this year to expand that indication to metastatic breast cancer, so that is not changing at all. The plant should be up and running in 2007."
Becker says the patients who died were using Avastin in combination with another drug.
Genentech's Oceanside plant employs several hundred people, and biotech courses at local college are preparing students to take new manufacturing jobs there next year. Alison St John, KPBS News.
To view PDF documents, Download Acrobat Reader.
Please stay on topic and be as concise as possible. Leaving a comment means you agree to our Community Discussion Rules. We like civilized discourse. We don't like spam, lying, profanity, harassment or personal attacks.